JumpCode Genomics, Inc. is a corporation organized in Delaware (formed more than five years before filing), based in San Diego, CA.
What this means A deal company is usually set up for one investment; its Form D is the notice it files after selling to investors.
It has filed 5 Form D filings (5 originals, 0 amendments) for 5 offerings between Sep 2018 and Aug 2024. The latest filing of each offering reports a combined $38.7M sold of $53.6M offered to 25 investors; industry as reported: industry reported as "Other", biotechnology; latest exemption Rule 506(b).
What this means A repeat filer — 5 separate raises over about 6 years. Amendments are routine updates (an ongoing raise must update its Form D at least once a year).
Key people as listed: Court Turner (director), David Michael Salter (executive officer and director), Joseph Lee (director), Brandon Poe (executive officer), Dan Kidle (director) and 8 more.
What this means These are the people the company itself named as running or promoting it. Tap a name to see every other deal they are on.
No sales commissions, finder's fees or proceeds to insiders are reported. No sales-compensation recipients are listed.
What this means No broker was paid — the sponsor sold it directly to investors.
Activity: 0 new offerings in the last 12 months; no amendment on file; latest filing Aug 22, 2024.
What this means No new raise filed in the past year — this deal company may be done raising, or simply quiet.
Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched JumpCode Genomics, Inc..
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA), property records (NYC, FL, IL and TX counties) — none found.
What this means Nothing turned up where we looked (4 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 5 public filings for JumpCode Genomics, Inc. and found 5 differences: Keith Brown's role changed at JumpCode Genomics, Inc.: executive officer, director → executive officer; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.